Aurobindo Pharma Limited has issued another clarification to stock exchanges regarding significant volume movement in its shares, maintaining its position that the activity remains linked to government policy changes affecting the pharmaceutical sector. The company provided the latest clarification on February 2, 2026, responding to fresh queries from the National Stock Exchange of India Limited dated February 1, 2026.

Updated Exchange Communication

The pharmaceutical company reiterated its stance on the trading volume increase, emphasizing that the movement continues to be market-driven following the government's Minimum Import Price notification. The latest communication reinforces the company's previous explanation while addressing renewed exchange scrutiny.

Government MIP Policy Impact

The company continues to highlight the connection between the share volume movement and the Government of India's notification imposing Minimum Import Price on specific pharmaceutical compounds. The policy covers imports intended for domestic consumption and directly impacts products manufactured by the company's subsidiary.

Media Coverage and Public Domain Information

Aurobindo Pharma specifically addressed media coverage surrounding the potential impact of the MIP policy, noting that all relevant information was already available through official government channels. The company emphasized that details were published on the Government's DGFT website, making the information publicly accessible to all market participants.

The pharmaceutical company clarified that since the MIP notification represents general industry policy rather than company-specific developments, no separate disclosure was required under regulatory guidelines. This distinction helps explain why the volume movement appears to be driven by market interpretation rather than undisclosed corporate information.

Regulatory Compliance Reaffirmation

In its latest communication, the company reaffirmed its commitment to maintaining continuous compliance with disclosure obligations. Aurobindo Pharma emphasized its track record of making timely and adequate disclosures of all material events and information in strict adherence to SEBI regulations.

The company confirmed that as of the latest clarification date, there remains no other information or pending announcements that could impact the price or volume movement of its securities, providing continued transparency to investors and market participants.

Source:

Aurobindo Pharma Limited has established a new wholly owned subsidiary in the Philippines as part of its international expansion strategy. The pharmaceutical company announced the incorporation of Aurobindo Pharma Philippines Inc. on January 23, 2026, through its existing subsidiary structure.

Subsidiary Structure and Ownership

The new Philippine entity has been incorporated as a wholly owned subsidiary of Helix Healthcare B.V., which is based in the Netherlands and serves as a wholly owned subsidiary of Aurobindo Pharma Limited. This creates a step-down subsidiary structure that enables the company to expand its operations in the Southeast Asian market.

Financial Investment and Share Capital

The newly incorporated subsidiary has been established with substantial initial funding to support its operations in the Philippines market. The company has made a complete cash subscription to the share capital structure.

Business Objectives and Market Expansion

The primary objective behind establishing Aurobindo Pharma Philippines Inc. is to expand the company's pharmaceutical products business in the Philippines. This strategic move aligns with the company's core pharmaceutical operations and represents a natural extension of its existing business model into new geographic markets.

The subsidiary will operate in the pharmaceuticals industry, focusing on expanding the reach of Aurobindo Pharma's product portfolio in the Philippine market. As a newly incorporated entity, the company does not have historical turnover data, but it is positioned to leverage the parent company's extensive pharmaceutical expertise and product range.

Regulatory Compliance and Approvals

The incorporation process was completed without requiring any governmental or regulatory approvals, indicating a streamlined establishment process. The transaction has been structured as a related party transaction due to the subsidiary relationship, though promoters and the promoter group of Aurobindo Pharma Limited have no direct interest in this particular transaction.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with stakeholders and regulatory authorities. This regulatory filing demonstrates the company's commitment to maintaining proper corporate governance standards in its expansion activities.